<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01628445</url>
  </required_header>
  <id_info>
    <org_study_id>U1111-1126-3937</org_study_id>
    <nct_id>NCT01628445</nct_id>
  </id_info>
  <brief_title>Study of Liraglutide in Individuals With Type 2 Diabetes Using Insulin</brief_title>
  <acronym>SAIL</acronym>
  <official_title>Phase 3 Study of Liraglutide in Individuals With Type 2 Diabetes Using Insulin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Manitoba</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Manitoba</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Liraglutide is a GLP1 agonist used in the treatment of Type 2 diabetes and is is asociated
      with improved blood glucose control, weight loss and low rates of hypoglycemia when used
      alone or in combination with metformin. Liraglutide has not been extensively tested in people
      with type 2 diabetes who are taking relatively large doses of insulin (&gt;50 U/day). Often
      these patients are insulin resistant and despite using large doses of insulin are not able to
      achieve glucose targets. The rationale for this study is to assess if the addition of
      liraglutide in addition to usual care versus placebo can improve blood glucose levels in
      people not achieving a target HbA1C of less than 7.0%.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Error made by local pharmacy caused mixed randomization of 20 participants
  </why_stopped>
  <start_date>August 2012</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in A1c</measure>
    <time_frame>Baseline to 24 wks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients experiencing hypoglycemia</measure>
    <time_frame>Baseline and 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Systolic Blood pressure</measure>
    <time_frame>Baseline and 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in diastolic blood pressure</measure>
    <time_frame>Baseline and 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in waist circumference</measure>
    <time_frame>Baseline and 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in body weight</measure>
    <time_frame>Baseline and 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in heart rate</measure>
    <time_frame>Baseline and 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in lipid profile</measure>
    <time_frame>Baseline and 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diabetes Treatment Satisfaction</measure>
    <time_frame>Baseline, 12 weeks and 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients achieving A1C &lt; or equal to 7%</measure>
    <time_frame>Baseline and 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fasting blood glucose</measure>
    <time_frame>Baseline adn 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurence of undetected hypoglycemia as measured by continuous glucose monitoring</measure>
    <time_frame>Baseline, 12 weeks and 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postprandial glucose reduction through measurement of 7 point glucose profile</measure>
    <time_frame>Baseline, 4 weeks, 12 weeks and 24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>liraglutide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>liraglutide 1.8 mg injected once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo injection</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>liraglutide</intervention_name>
    <description>liraglutide titrated to 1.8 mg sc daily</description>
    <arm_group_label>liraglutide</arm_group_label>
    <other_name>Victoza</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo injection</intervention_name>
    <description>placebo injected sc daily volume equal to active comparator</description>
    <arm_group_label>Placebo injection</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetes

          -  BMI≤45 kg/m2

          -  A1c ≥7.5% and ≤10.5%

        Exclusion Criteria:

          -  type 1 diabetes

          -  symptoms of poorly controlled diabetes

          -  eGFR &lt;50 ml/min/1.73m2
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vincent C Woo, MD FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Mantioba</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Winnipeg Regional Health Authority Health Sciences Centre Winnipeg Diabetes Research Group</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3E3P4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 21, 2012</study_first_submitted>
  <study_first_submitted_qc>June 22, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 26, 2012</study_first_posted>
  <last_update_submitted>January 20, 2016</last_update_submitted>
  <last_update_submitted_qc>January 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Manitoba</investigator_affiliation>
    <investigator_full_name>Dr. Vincent Woo</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Diabetes</keyword>
  <keyword>Insulin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Liraglutide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

